Hematology/Oncology

Top Story

Chemoimmunotherapy combination ‘new standard’ for CNS lymphoma

July 26, 2016

The addition of rituximab to thiotepa and methotrexate–cytarabine increased the complete remission rate among patients with central nervous system lymphoma, according to results from the first randomization of the phase 2 IELSG32 trial.

However, the combination, also called the MATRix regimen, also caused more grade 3 to grade 4 adverse events.

Radiosurgery alone lessens cognitive decline for patients with limited brain metastases

July 26, 2016
The use of stereotactic radiosurgery without adjuvant whole-brain radiation lessened cognitive deterioration at 3 months among patients with one to three brain…
FDA News

FDA grants breakthrough therapy designation to Darzalex for multiple myeloma

July 26, 2016
The FDA granted breakthrough therapy designation to daratumumab for its use in combination with standard-of-care regimens for patients with

IMRT for prostate cancer does not increase risk for leukemia, myelodysplasia

July 26, 2016
Intensity-modulated radiation therapy for the treatment of prostate cancer did not increase the risk for leukemia or myelodysplasia compared with 3-dimensional conformal…

Second malignancies, death common among cancer survivors

July 25, 2016
Approximately one in 12 patients with a common primary tumor were diagnosed with a second primary malignancy between 1992 and 2008, according to results of a SEER…
More News Headlines »
CME

The Patient with Myelofibrosis

No commercial support for this activity.

Myelofibrosis is caused by abnormal stem cells in the bone marrow that cause the uncontrolled production of mature…
More »
Video
At Issue

VIDEO: Multiple myeloma treatments evolve as access to new technology improves

July 12, 2016
More »
Featured
2016 ASCO Annual Meeting

2016 ASCO Annual Meeting

CME

Management of Multiple Myeloma: Using Emerging Therapies with ASCT

This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Spectrum Pharmaceuticals, Inc.; and Takeda Oncology.

Multiple myeloma management has undergone profound changes in the past few decades, this is largely due to advances in…
More »
Current Issues
View the Current Issue
HemOnc Today
morganatic-roan
morganatic-roan